Loading cancer entity…
Loading cancer entity…
Clinical trials
10,628 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,642)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05227144 | Study of ORIC-533 in Relapsed or Refractory Multiple Myeloma | completed | Phase 1 | 31 | ORIC PharmaceuticalsINDUSTRY | 2 | Mar 20, 2025 | clinicaltrials |
| NCT05225584 | Safety, PK, PD, Clinical Activity of KT-333 in Adult Patients With Refractory Lymphoma, Large Granular Lymphocytic Leukemia, Solid Tumors | completed | Phase 1 | 56 | Kymera Therapeutics, Inc.INDUSTRY | 1 | Mar 19, 2025 | clinicaltrials |
| NCT03269136 | PF-06863135 As Single Agent And In Combination With Immunomodulatory Agents In Relapse/Refractory Multiple Myeloma | completed | Phase 1 | 101 | PfizerINDUSTRY | 2 | Mar 18, 2025 | clinicaltrials |
| NCT01497184 | Infusion of Allogeneic CD19-Specific T Cells From Peripheral Blood | completed | Phase 1 | 95 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 13, 2025 | clinicaltrials |
| NCT01701986 | Gemcitabine Hydrochloride, Clofarabine, and Busulfan Before Donor Stem Cell Transplant in Treating Patients With Refractory B-Cell or T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 64 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 28, 2025 | clinicaltrials |
| NCT03058289 | A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6(IT-01) | completed | Phase 1 / Phase 2 | 111 | Intensity Therapeutics, Inc.INDUSTRY | 2 | Feb 27, 2025 | clinicaltrials |
| NCT05844956 | A Study of DZD8586 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (TAI-SHAN1) | completed | Phase 1 / Phase 2 | 17 | Dizal PharmaceuticalsINDUSTRY | 1 | Feb 21, 2025 | clinicaltrials |
| NCT00788684 | Safety Study of ABT-263 in Combination With Rituximab in Lymphoid Cancers | completed | Phase 1 | 29 | AbbVieINDUSTRY | 2 | Feb 20, 2025 | clinicaltrials |
| NCT04537715 | Effects of Itraconazole and Rifampin on the Blood Tazemetostat Levels | completed | Phase 1 | 42 | Epizyme, Inc.INDUSTRY | 2 | Feb 19, 2025 | clinicaltrials |
| NCT03190174 | Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers | completed | Phase 1 / Phase 2 | 34 | Sarcoma Oncology Research Center, LLCOTHER | 1 | Feb 17, 2025 | clinicaltrials |
| NCT05243342 | A Study to Evaluate the Safety and Pharmacokinetics of XMAB24306 in Combination With Daratumumab in Participants With Relapsed/Refractory Multiple Myeloma | completed | Phase 1 | 18 | Genentech, Inc.INDUSTRY | 4 | Feb 17, 2025 | clinicaltrials |
| NCT03654716 | Phase 1 Study of the Dual MDM2/MDMX Inhibitor ALRN-6924 in Pediatric Cancer | completed | Phase 1 | 21 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 14, 2025 | clinicaltrials |
| NCT03732703 | Myeloma-Developing Regimens Using Genomics (MyDRUG)(MyDRUG) | completed | Phase 1 / Phase 2 | 103 | Multiple Myeloma Research ConsortiumNETWORK | 1 | Feb 14, 2025 | clinicaltrials |
| NCT03088878 | A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies | completed | Phase 1 / Phase 2 | 95 | Oncternal Therapeutics, IncINDUSTRY | 1 | Feb 12, 2025 | clinicaltrials |
| NCT01638533 | Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction | completed | Phase 1 | 37 | National Cancer Institute (NCI)NIH | 2 | Feb 7, 2025 | clinicaltrials |
| NCT02245867 | Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients With AL Amyloidosis | completed | Phase 1 | 30 | Alexion Pharmaceuticals, Inc.INDUSTRY | 1 | Feb 7, 2025 | clinicaltrials |
| NCT03762291 | Multiple Myeloma Trial of Orally Administered Salmonella Based Survivin Vaccine(MAPSS) | completed | Phase 1 | 1 | Baylor College of MedicineOTHER | 1 | Feb 5, 2025 | clinicaltrials |
| NCT04599634 | Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies | completed | Phase 1 | 11 | National Cancer Institute (NCI)NIH | 1 | Feb 4, 2025 | clinicaltrials |
| NCT05665725 | Siltuximab for the Prevention of CAR T Cell Related Cytokine Release Syndrome in Patients With CD19 Positive Non-Hodgkin Lymphoma | completed | Phase 1 | 11 | Timothy VoorheesOTHER | 1 | Jan 31, 2025 | clinicaltrials |
| NCT05775406 | Safety and Clinical Activity of KT-253 in Adult Patients with High Grade Myeloid Malignancies, Acute Lymphocytic Leukemia, Lymphoma, Solid Tumors | completed | Phase 1 | 52 | Kymera Therapeutics, Inc.INDUSTRY | 1 | Jan 27, 2025 | clinicaltrials |
| NCT04634435 | Autologous Memory-like NK Cell Therapy With BHV-1100 and Low Dose IL-2 in Multiple Myeloma Patients | completed | Phase 1 | 7 | Biohaven Pharmaceuticals, Inc.INDUSTRY | 1 | Jan 20, 2025 | clinicaltrials |
| NCT04774068 | Romidepsin and Parsaclisib for the Treatment of Relapsed or Refractory T-Cell Lymphomas | completed | Phase 1 | 5 | Walter HanelOTHER | 1 | Jan 17, 2025 | clinicaltrials |
| NCT02323880 | Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas | completed | Phase 1 | 59 | Children's Oncology GroupNETWORK | 1 | Jan 14, 2025 | clinicaltrials |
| NCT03773107 | LCI-HEM-MYE-CRD-004 (MMRC-073 CARJAK): Study of CRD for Carfilzomib-Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 12 | Wake Forest University Health SciencesOTHER | 1 | Jan 13, 2025 | clinicaltrials |
| NCT00670358 | Lenalidomide, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large Cell or Follicular B-Cell Lymphoma | completed | Phase 1 / Phase 2 | 138 | Mayo ClinicOTHER | 1 | Jan 10, 2025 | clinicaltrials |
| NCT04841434 | A Phase I/II Study to Investigate the Use of VORAXAZE™ As Intended Intervention in Patients with CNSL(VALIDATE) | completed | Phase 1 / Phase 2 | 18 | Charite University, Berlin, GermanyOTHER | 1 | Jan 6, 2025 | clinicaltrials |
| NCT03997968 | A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 169 | Cyteir Therapeutics, Inc.INDUSTRY | 1 | Dec 24, 2024 | clinicaltrials |
| NCT00243087 | Investigation of Safety, Tolerability and Maximum Tolerated Dose (MTD) of BI 2536 in Patients With Recurrent Advanced Aggressive Non-Hodgkin's Lymphoma (NHL) | completed | Phase 1 | 41 | Boehringer IngelheimINDUSTRY | 1 | Dec 20, 2024 | clinicaltrials |
| NCT02112526 | Acalabrutinib (ACP-196), a Btk Inhibitor, for Treatment of de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma | completed | Phase 1 | 21 | Acerta Pharma BVINDUSTRY | 2 | Dec 20, 2024 | clinicaltrials |
| NCT01956084 | Cytotoxic T Cells to Treat Relapsed EBV-positive Lymphoma(ALCI2) | completed | Phase 1 | 10 | Catherine BollardOTHER | 1 | Dec 19, 2024 | clinicaltrials |
| NCT03677141 | A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 117 | Hoffmann-La RocheINDUSTRY | 6 | Dec 18, 2024 | clinicaltrials |
| NCT03129828 | Ibrutinib, Bortezomib and Rituximab-CHOP for the Treatment of Elderly Patients With CD20+ DLBCL, IPI ≥ 2(ImbruVeRCHOP) | completed | Phase 1 / Phase 2 | 38 | Prof. Dr. Clemens SchmittOTHER | 1 | Dec 13, 2024 | clinicaltrials |
| NCT04136275 | CAR-37 T Cells in Hematologic Malignancies | completed | Phase 1 | 6 | Marcela V. Maus, M.D.,Ph.D.OTHER | 1 | Dec 12, 2024 | clinicaltrials |
| NCT03410901 | TLR9 Agonist SD-101, Anti-OX40 Antibody BMS 986178, and Radiation Therapy in Treating Patients With Low-Grade B-Cell Non-Hodgkin Lymphomas | completed | Phase 1 | 14 | Ronald LevyOTHER | 1 | Dec 11, 2024 | clinicaltrials |
| NCT03030417 | Indenoisoquinoline LMP744 in Adults With Relapsed Solid Tumors and Lymphomas | completed | Phase 1 | 36 | National Cancer Institute (NCI)NIH | 1 | Dec 10, 2024 | clinicaltrials |
| NCT05233033 | Safety, PK/PD, and Clinical Activity of KT-413 in Adult Patients with Relapsed or Refractory B-cell NHL | completed | Phase 1 | 7 | Kymera Therapeutics, Inc.INDUSTRY | 2 | Dec 10, 2024 | clinicaltrials |
| NCT03664635 | MB-CART20.1 Lymphoma | completed | Phase 1 / Phase 2 | 10 | Miltenyi Biomedicine GmbHINDUSTRY | 1 | Nov 21, 2024 | clinicaltrials |
| NCT05896774 | A Study to Learn About the Study Medicine (Maplirpacept) in People With Advanced Non-Hodgkin Lymphoma or Multiple Myeloma in China | completed | Phase 1 | 10 | PfizerINDUSTRY | 1 | Nov 20, 2024 | clinicaltrials |
| NCT02268851 | A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL or MCL | completed | Phase 1 | 45 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 15, 2024 | clinicaltrials |
| NCT04840875 | Phase I Clinical Trial of Autologous CD7-CAR T Cell Therapy for High-risk Acute T-cell Leukemia/lymphoma | completed | Phase 1 | 16 | Beijing Boren HospitalOTHER | 1 | Nov 14, 2024 | clinicaltrials |
| NCT01857115 | Study of Weekly Carfilzomib, Cyclophosphamide and Dexamethasone In Newly Diagnosed Multiple Myeloma Patients (wCCyd)(wCCyd) | completed | Phase 1 / Phase 2 | 63 | European Myeloma Network B.V.NETWORK | 1 | Nov 13, 2024 | clinicaltrials |
| NCT02043847 | TMI With HD Mel in ASCT for R/R Multiple Myeloma (BMT-03)(BMT-03) | completed | Phase 1 | 12 | University of Illinois at ChicagoOTHER | 1 | Nov 13, 2024 | clinicaltrials |
| NCT02924402 | Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic Malignancies | completed | Phase 1 | 154 | Xencor, Inc.INDUSTRY | 4 | Nov 13, 2024 | clinicaltrials |
| NCT05269940 | A Study to Evaluate Activity, Safety and Tolerability of ZX-101A in Relapsed/Refractory Hematological Malignancies | completed | Phase 1 / Phase 2 | 40 | Nanjing Zenshine PharmaceuticalsINDUSTRY | 1 | Nov 13, 2024 | clinicaltrials |
| NCT03524235 | Haploidentical Stem Cell Transplant with Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLL | completed | Phase 1 | 20 | Noah MerinOTHER | 1 | Nov 12, 2024 | clinicaltrials |
| NCT01755975 | Romidepsin in Combination With Lenalidomide in Adults With Relapsed or Refractory Lymphomas and Myeloma | completed | Phase 1 / Phase 2 | 49 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 7, 2024 | clinicaltrials |
| NCT05567887 | A Study to Learn About the Study Medicine (Called Maplirpacept (PF-07901801)) in Japanese With Hematologic Malignancies | completed | Phase 1 | 7 | PfizerINDUSTRY | 1 | Nov 6, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Mar 20, 2025source: clinicaltrials